Cor Vasa 2006, 48(10):361-364 | DOI: 10.33678/cor.2006.115

Nové britské směrnice o léčbů hypertenze

Jifií Widimský
Klinika kardiologie, Institut klinické a experimentální medicíny, Subkatedra kardiologie IPVZ, Praha, Česká republika

Published: October 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. Nové britské směrnice o léčbů hypertenze. Cor Vasa. 2006;48(10):361-364. doi: 10.33678/cor.2006.115.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. www.nice.org.uk/CG034NICEguideline.
    2. Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985;27: 335-71. Go to original source... Go to PubMed...
    3. Held PH, Yusuf S. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 1993;14 (Suppl F):18-25. Go to original source... Go to PubMed...
    4. The CAPRICORN Investigators. Effects of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90. Go to original source... Go to PubMed...
    5. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 1999; 318:1730-7. Go to original source... Go to PubMed...
    6. Boissel JP, Leizorovicz A, Picolet H, et al. Efficacy of acebutolol after acute myocardial infarction. (The APSI Trial). Am J Cardiol 1990;66:24C-31C. Go to original source... Go to PubMed...
    7. CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II. (CIBIS-II). Lancet 1999; 353:9-13. Go to original source...
    8. MERIT-HF Study Group. Effect of Metoprolol CR/XL in Chronic Heart Failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7. Go to original source...
    9. Packer M, Fowler MB, Roecker EB, et al. for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002;106:2194-9. Go to original source... Go to PubMed...
    10. Cleland JGF, Cohen-Solal A, Cosin Aguilar J, et al. for the IMPROVEMENT of Heart Failure Programme Committees and Investigators and the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an International Survey. Lancet 2002;360:1631-9. Go to original source... Go to PubMed...
    11. Komajda M, Follath F, Swedberg K, et al. for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Euro Heart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:464-75. Go to original source... Go to PubMed...
    12. Widimský J, Lánská V, Magulová D, Sachová M. Průzkum stavu aktuální praxe diagnostiky a léčby srdečního selhání v ordinacích všeobecných lékařů v České a Slovenské republice v roce 1999. 2. část programu IMPROVEMENT of HF. Cor Vasa 2001;54:345-54.
    13. Widimský J, Špinar J. Nedostatky léčby srdečního selhání v Evropě. Zaostává klinická praxe za evropskými směrnicemi? Zaostává Česká republika za Evropou? Cor Vasa 2003;45: 481-5.
    14. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364: 1684-9. Go to original source... Go to PubMed...
    15. Dahlöf B, Devereux RB, Kjeldsen SE, et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003 Go to original source... Go to PubMed...
    16. Dahlöf B, Sever PS, Poulter NE, et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366: 895-906. Go to original source... Go to PubMed...
    17. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366: 1545-53. Go to original source... Go to PubMed...
    18. Widimský J. Klady a úskalí "evidence based" medicíny. Cor Vasa 2006;48:24-31. Go to original source...
    19. Widimský J, sr. Studie ASCOT-BPLA. Léčba opírající se o amlodipin ± perindopril poskytuje lepší výsledky než léčba opírající se o atenolol ± bendroflumethiazid v léčbě hypertenze. Cor Vasa 2005;47:437-40.
    20. Williams B, Lacy PS, Tom SM, et al. for the CAFE Steering Committee and Writing Committee. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Circulation 2006;113: 1213-25. Go to original source... Go to PubMed...
    21. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289:2560-72. Go to original source... Go to PubMed...
    22. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53. Go to original source... Go to PubMed...
    23. Cífková R, Horký K, Widimský J sr., a spol., za Českou společnost pro hypertenzi. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení České společnosti pro hypertenzi. Cor Vasa 2005;47:K3-K16.

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes